



June 16, 2025

National Stock Exchange of India Limited

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
Mumbai - 400 051

BSE Limited

P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
Mumbai - 400 001

Symbol: LUPIN

Scrip Code: Equity - 500257

Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations').

Dear Sir/Madam,

We are pleased to enclose a Press Release as regards, the Company having signed a license and supply agreement with Sino Universal Pharmaceuticals, for the commercialization of Tiotropium Dry Powder Inhaler, 18 mcg/capsule, in the Chinese market, for the treatment of chronic obstructive pulmonary disease.

The same is for your information and dissemination.

Thanking you,

For LUPIN LIMITED

**AMIT KUMAR GUPTA
COMPANY SECRETARY & COMPLIANCE OFFICER
(ACS -15754)**

Encl: a/a.

LUPIN LIMITED

Registered Office: 3rd Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323.

Corporate Identity Number: L24100MH1983PLC029442

www.lupin.com

Lupin and Sino Universal Pharmaceuticals Sign License and Supply Agreement for Tiotropium DPI in China

Aim to expand healthcare solutions in China

Mumbai, Naples, Fuzhou, China, June 16, 2025: Global pharma major Lupin Limited (Lupin) today announced that it has signed a license and supply agreement with Sino Universal Pharmaceuticals (SUP), for the commercialization of Tiotropium Dry Powder Inhaler (DPI), 18 mcg/capsule, in the Chinese market, for the treatment of chronic obstructive pulmonary disease (COPD).

As per the agreement, SUP will obtain regulatory approvals for selling Tiotropium DPI in China, while Lupin will be the marketing authorization holder and responsible for manufacturing of the product.

Tiotropium DPI is known for its efficacy in improving lung function and quality of life for patients suffering from respiratory conditions. This partnership will enable Lupin to expand its footprint in China, ensuring that patients have timely access to innovative and high-quality healthcare solutions, considering the increasing prevalence of respiratory conditions.

"We are very pleased to partner with SUP to bring Tiotropium DPI to patients in China," said **Fabrice Egros, President of Corporate Development, Lupin**. "This partnership demonstrates our commitment to developing critical products for the treatment of respiratory diseases such as COPD and establishing our leadership in the global respiratory health sector. SUP is our esteemed partner in this endeavor, and together we aim to enhance patient access to innovative and high-quality healthcare solutions."

"We are truly honored to partner with Lupin, a global pharmaceutical leader, on Tiotropium DPI," said **Wang Li, President of SUP**. "Lupin's deep commitment to respiratory disease treatment and its innovation-driven approach to high-quality products align perfectly with SUP's strategic vision. We believe this collaboration will strengthen our synergy in respiratory care. By bringing more efficient and superior products to market, we aim to make significant breakthroughs in respiratory disease treatment in China, allowing more patients to benefit from international high-quality and innovative products and enjoy respiratory health."

About Lupin

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries - Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

To know more, visit www.lupin.com or follow us on LinkedIn <https://www.linkedin.com/company/lupin>

BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

About Sino Universal Pharma (SUP)

Sino Universal Pharma is a global one-stop pharmaceutical distribution management service provider that has been active in the pharmaceutical industry for over 18 years. The company is based in China and is committed to enhancing pharmaceutical distribution and management services. Over the past few years, Sino Universal Pharma has successfully partnered with numerous leading pharma companies worldwide. Through these collaborations, it has effectively introduced a wide array of outstanding products into the Chinese market, playing a crucial role in bridging the gap between global innovation and local healthcare needs, and making significant contributions to improving the availability and accessibility of high-quality products for Chinese patients. <https://en.supgroups.com/>

For further information or queries please contact:

Rajalakshmi Azariah

Vice President & Global Head – Corporate Communications, Lupin

rajalakshmiazariah@lupin.com